Clinical Trials Arena on MSN
BMS to speak with regulators on mid-stage multiple myeloma success
An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.
US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...
The Plant Cell, Vol. 30, No. 1 (January 2018), pp. 228-244 (18 pages) Cuticular wax plays crucial roles in protecting plants from environmental stresses, particularly drought stress. Many ...
Newco Outrun Therapeutics Ltd. has raised $10 million in a seed round to develop small-molecule E3 ubiquitin ligase inhibitors that prevent programmed protein degradation. The lead program targeting ...
Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ...
MISFOLDED PROTEIN SENSING RING1 (MPSR1) is a chaperone-independent E3 ubiquitin ligase that participates in protein quality control by eliminating misfolded proteins in Arabidopsis (Arabidopsis ...
Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback